Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients.

Severe Pneumocystis pneumonia in a renal transplant recipient after long term mycophenolate mofetil treatment.

[First successful bridge to cardiac transplantation in Chile using the Heart Mate II device. Report of one case].

Implantable ventricular assist devices are an effective treatment option for end-stage heart failure patients as a bridge to cardiac transplantation, to improve the clinical condition and organ function allowing discharge from the hospital to await for transplantation. The second alternative is to use the device as destination therapy for patients with contraindications for cardiac transplantat...

Introduction of a Case of Interstitial Pneumonia Related to Pneumocystis Carinii

This article has no abstract.

The evolving role of mycophenolate mofetil in renal transplantation.

Mycophenolate mofetil (MMF) is an ester prodrug tial interest in organ transplantation is the inhibitory with higher bioavailability than the active agent, effect of MPA on the proliferation of human arterial mycophenolic acid (MPA).1 MPA inhibits inosine smooth muscle cells in vitro. Arterial disease plays monophosphate (IMP) dehydrogenase, an enzyme a central role in chronic graft rejection, ...

Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Passive antibody immunoprophylaxis is one method used to protect patients against infection if they are unable to mount an adequate active immune response. Topical application of antibody may be effective against infections at mucosal sites. Using a SCID mouse model of Pneumocystis carinii pneumonia, we were able to demonstrate protection against an airborne challenge with P. carinii by intrana...